Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
10.98
+0.19 (1.76%)
Jan 12, 2026, 4:00 PM EST - Market closed
Crescent Biopharma Stock Forecast
Stock Price Forecast
The 5 analysts that cover Crescent Biopharma stock have a consensus rating of "Strong Buy" and an average price target of $25.6, which forecasts a 133.15% increase in the stock price over the next year. The lowest target is $22 and the highest is $28.
Price Target: $25.6 (+133.15%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 27, 2025.
Analyst Ratings
The average analyst rating for Crescent Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +127.69% | Aug 27, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +136.79% | Aug 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +127.69% | Aug 11, 2025 |
| Wedbush | Wedbush | Buy Initiates $27 | Buy | Initiates | $27 | +145.90% | Jul 14, 2025 |
| Stifel | Stifel | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +155.01% | Jun 25, 2025 |
Financial Forecast
Revenue This Year
5.10M
Revenue Next Year
n/a
from 5.10M
EPS This Year
-7.80
from -13.45
EPS Next Year
-5.51
from -7.80
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 21.0M | n/a | ||||
| Avg | 5.1M | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -8.03 | -3.07 | ||||
| Avg | -7.80 | -5.51 | ||||
| Low | -7.50 | -10.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.